Over 19 years of experience in R&D

Learn more

01 Drug Discovery

Chemistry Research

Fee For Service(FFS)

Full Time Equivalent(FTE)

Computational Biology & Molecular Modeling

Enzymology & Molecular Interactions

Early Pharmacokinetics

02 Pharmaceutical Research

Intermediates

APIs

Route Selection

Production Process Optimization

Clinical Sample Production

Impurity Traceability & Control

Generic Drug Process Study & Filing

Innovative Drug Process Study & Filing

Pharmaceutical preparation

Preformulation Study

Formulation Technology Research

Preparation Quality Research

Laboratory-scale Preparation Testing

Pilot-scale Preparation Testing

GMP-based Clinical Sample Production & Packaging

Formulation Stability Study

Consistency Evaluation

Analytical Method Development and Quality Control

CMC Filings

03 Preclinical Research

Pharmacology & Pharmacodynamics

Tumor Models

Digestive System Disease Models

Endocrine & Metabolic Disease Models

Inflammatory & Immune Diseases Models

Neural System Disease Models

Other Disease Models

Drug Safety Evaluation

Pharmacology & Toxicology Study

Safety Pharmacology

Histopathological Study

Clinicopathological Study

Drug Safety Evaluation Basic Information

Toxicokinetics

Pharmacokinetics

In Vitro Pharmacokinetic Assays

In Vivo Pharmacokinetic Assays

Bioanalysis

Macromolecular Drugs Bioanalysis

Micromolecular Drugs Bioanalysis

IND Filings

01 One-stop Integrated Services

Pharmaceutical Research Platform

Drug Discovery Plarform

One-stop API Process R&D Department

Translational Medicine Platform

Pharmaceutical Research CDMO Service Platform

Chemical Drug Development

Medicilon's CDMO Service Platform

Preclinical Research Services

02 Key Technical Services for Drug R&D

Process Department Solid Form Screening Platform

SEND Format Conversion Platform

Flow Cytometry Technology Platform

Safety Assessment Lab of Process Chemistry

Drug Forming Research Platform

Metabolite Identification (MetID) Service Platform

Cytokine and Biomarker Detection Platform

03 Innovative Drug Services

Nucleic Acid Drug R&D Platform

Non-clinical Research for Cellular Immunotherapies

mRNA Vaccine Bioanalysis Platform

PROTAC Drug Discovery Research Platform

ADC R&D Service Platform

04 Drug Efficacy Evaluation for Common Diseases

Rodent Cerebrovascular Disease Drug Efficacy Evaluation System

Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases

IO Pharmacodynamic Model Evaluation Platform

05 Advanced Preparation R&D

Skin Topical Preparation R&D

Ophthalmic drug R&D platform

Inhalation drug R&D platform

06 Drug Analysis

07 Public Services

CLIENT CENTER

Intellectual Property Protection

Downloads

Partnerships

Newsletters

U.S.

Address: 1 Broadway, Cambridge, MA02142 (America)

Tel: +1(626)986-9880

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

2023-03-14Market Events

Join Medicilon at BioTrinity 2023: Catalysing Growth in the Life Sciences Industry

Date: April 25-26, 2023

Location: Etc. venues 155 Bishopsgate, London

Learn more

2023-03-03Featured Stories

Whole-Process of Antibody Drug Development - Facilitate IND Declaration of Biological Drugs

The Medicilon antibody development platform has been deeply involved in the field of antibody drug research and development and their technical services include the ADA antibody development technical services and druggable antibody development technical services, ADA-free polyclonal antibody development, ADA mouse hybridoma monoclonal antibody development, phage display rabbit monoclonal antibody development services, mouse monoclonal antibody development technical services, mouse/rabbit single B cell antibody development technical services and other projects.

Medicilon 688202

RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

Shanghai Public Network Security File No. 31011502018888 | Website Map

Business Inquiry

Global：

Email:marketing@medicilon.com

+1(626)986-9880(U.S. - West Coast)

0044 7790 816 954 (Europe)

China：

Email: marketing@medicilon.com.cn

Tel: +86 (21) 5859-1500

Medicilon held the Preclincial and IND Declaration Seminar in Chengdu, China

2019-01-10

Page View：

Preclincial-and-IND-Declaration — Preclincial and IND Declaration

Medicilon CEO Chun-Lin Chen gave a speech during the seminar where he shared his experience on IND filling for both US and China.

Professor Shuangqing Peng had a topic on **New Drug Safety Evaluation Approach**.

Dr. Baomin Xin, Medicilon VP of DMPK and BA, shared his experience on big molecule analytical approach and future trend, shifting from Pharma to Biopharma.

Executive Director of DMPK — Dr. Fei Ma, Executive Director of #DMPK, introduced a new idea of DMPK, including the ideal DMPK research model, DMPK activities during #Drug discovery.

Medicilon VP of Toxicology — Professor Xiaodong Zhang is #Medicilon VP of #Toxicology.

Dr. Zheyi Hu, Director of Pharmacology, shared his experience on oncology animal models.

Medicilon’s IND Filing-innovative drug research and development

Medicilon’s IND Application Platform

IND Enabling Studies FDA

Medicilon successfully held CFDA IND seminar in Seoul, South Korea

Medicilon sponsored the seminar on new drug preclinical research and IND application strategy

IND Filing

IND-Declaration-Seminar IND-filling

Return

Relevant news